Home › Research › Tau biomarkers
ERK2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients
Petra Steinacker, Hans Klafki, Stefan Lehnert, Sarah Jesse, Christine A F V Arnim, Hayrettin Tumani, Alice Pabst, Hans A Kretzschmar et al.. Journal of Alzheimer's disease : JAD, 2010
Topic: Disease mechanisms in lab and animal studies
Plain-language summary
The clinical diagnosis of Creutzfeldt-Jakob disease (CJD) can be supported by several biochemical markers in cerebrospinal fluid (CSF) such as 14-3-3 proteins and tau protein. Unfortunately, none of the currently known markers are suited for screening or seems to be directly related to the pathophysiological process. A marker fulfilling these criteria might facilitate the early detection and might also serve in monitoring drug efficacy. Recently, the extracellular signal-regulated kinase ERK1/2 was detected in CSF of patients with neuropsychiatric disorders. Furthermore, ERK1/2 was reported to be activated in brains of animals infected with pathological prion protein. Therefore, we investigated CSF of 19 patients with CJD, 23 patients with other dementias including patients with Alzheimer's disease, and 12 patients with other neurological disorders. The measurement of ERK1/2 in the CSF samples was performed with an electrochemiluminescence assay and Western immunoblot. ERK1/2 and doubly phosphorylated ERK1/2 (pERK1/2) were detected in all patient groups. Significantly elevated mean levels of total ERK1/2 and pERK1/2 were found in the CJD patients. This increase was also observed in a CJD case that was negative for 14-3-3 protein or in CJD cases that had low levels of tau protein. Western immunoblot analysis suggested that ERK2 was the predominant form of ERKs present in our CSF samples. This pilot study suggests that ERK1/2 is a potential CSF biomarker for CJD, directly associated with the pathophysiological processes. Analysis of larger sample cohorts including other diseases with rapid neurodegeneration are required to confirm our findings.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Steinacker, P., Klafki, H., Lehnert, S., Jesse, S., Arnim, C. A. F. V., Tumani, H., et al. (2010). ERK2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-2010-100030
Vancouver
Steinacker P, Klafki H, Lehnert S, Jesse S, Arnim CAFV, Tumani H, et al. ERK2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. Journal of Alzheimer's disease : JAD. 2010. doi:10.3233/jad-2010-100030. PMID: 20847405.
BibTeX
@article{steinacker2010-20847405,
author = {Steinacker, Petra and Klafki, Hans and Lehnert, Stefan and Jesse, Sarah and Arnim, Christine A F V and Tumani, Hayrettin and Pabst, Alice and Kretzschmar, Hans A and others},
title = {{ERK2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2010},
doi = {10.3233/jad-2010-100030},
pmid = {20847405},
url = {https://doi.org/10.3233/jad-2010-100030}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Significantly elevated mean levels of total ERK1/2 and pERK1/2 were found in the CJD patients.
- Western immunoblot analysis suggested that ERK2 was the predominant form of ERKs present in our CSF samples.
- This pilot study suggests that ERK1/2 is a potential CSF biomarker for CJD, directly associated with the pathophysiological processes.
- Analysis of larger sample cohorts including other diseases with rapid neurodegeneration are required to confirm our findings.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants19
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and free to read, so those were left out: it earned 27 of the 59 points we could judge it on, which is 46 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 19 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20847405) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 27 / 59 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 27 of the 59 points we could judge it on is 46 out of 100. |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also tagged “phosphorylation”
389 studies in the library carry the topic tag “phosphorylation”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 389 tagged studies.